Edit by Christine
Email: info@rimlessindustry.com
Recently, Reborn welcomed a group of physicians and medical partners from Russia to its manufacturing facility for a site visit and technical exchange.
The visit centered on Reborn’s PLLA biostimulator product system, with a close look at how finished products are manufactured, as well as a brief introduction to the upstream material preparation process. More than a technical tour, it was an open conversation about how regenerative aesthetics is evolving in clinical practice.
A closer look at PLLA biostimulator products
During the visit, the physicians spent time reviewing Reborn’s PLLA filler and biostimulator systems, focusing on how the products are designed to support gradual, natural-looking improvements in skin quality.
Unlike traditional fillers that provide immediate volume, PLLA works through a slower biological process. It stimulates the skin’s own response—encouraging collagen production and supporting the structure of the extracellular matrix over time.
Many of the questions from the visiting doctors focused on real clinical experience: how patients respond over time, how consistent the results are across different treatment areas, and how PLLA fits into combination protocols used in daily practice.
Inside the manufacturing process
The group was also introduced to Reborn’s manufacturing environment, where they observed key steps of the production process for PLLA-based products.
This included an overview of:
- microsphere formation and consistency control
- sterile production conditions
- batch testing and quality verification
- overall quality assurance standards for injectable devices
Rather than a purely technical presentation, the discussion often returned to one central point:
how each step in manufacturing eventually connects back to clinical predictability.
Understanding the material behind the product
In addition to finished products, the visit also included a brief look at the raw material preparation process behind PLLA.
This helped provide context for how medical-grade polymers are transformed into structured microspheres, and why small variations at the material level can influence how the product behaves once it is used in real clinical settings.
For many of the visiting physicians, this connection between material science and patient outcomes was one of the most valuable parts of the visit.
A shared view on where aesthetics is heading
Across the discussions, one theme came up repeatedly: aesthetic medicine is changing.
More clinicians are moving away from purely volume-based approaches and toward treatments that focus on skin quality, structure, and long-term regeneration.
PLLA is increasingly seen in this context—not simply as a filler, but as a tool that supports the skin’s own regenerative capacity over time.
Building understanding through direct exchange
The visit concluded with open discussions between the Russian physicians and the Reborn team, focusing on clinical experience, treatment design, and future collaboration.
While the technical aspects of the product were important, what stood out most was the value of direct, face-to-face exchange—seeing the manufacturing process in person and connecting it with everyday clinical practice.
Reborn will continue to welcome medical partners from different regions, with the aim of supporting clearer understanding and more consistent application of regenerative aesthetic treatments worldwide.
About Reborn
Reborn develops and manufactures PLLA-based regenerative injectable solutions designed to support collagen stimulation, skin quality improvement, and long-term aesthetic outcomes through medical-grade production standards.